Ryan CJ - Search Results

1

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer.

Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. Wei XX, et al. Among authors: ryan cj. Oncologist. 2017 May;22(5):503-e43. doi: 10.1634/theoncologist.2016-0432. Epub 2017 Mar 17. Oncologist. 2017. PMID: 28314838 Free PMC article. Clinical Trial.

2

Advances in prostate cancer.

Ryan CJ, Small EJ. Ryan CJ, et al. Curr Opin Oncol. 2004 May;16(3):242-6. doi: 10.1097/00001622-200405000-00009. Curr Opin Oncol. 2004. PMID: 15069320 Review.

3

Prostate cancer update: 2005.

Ryan CJ, Small EJ. Ryan CJ, et al. Curr Opin Oncol. 2006 May;18(3):284-8. doi: 10.1097/01.cco.0000219259.83585.f3. Curr Opin Oncol. 2006. PMID: 16552242 Review.

4

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.

Ryan CJ, Lin AM, Small EJ. Ryan CJ, et al. Urol Oncol. 2006 May-Jun;24(3):250-3. doi: 10.1016/j.urolonc.2005.11.021. Urol Oncol. 2006. PMID: 16678059 Review.

5

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. Lin AM, et al. Among authors: ryan cj. BJU Int. 2006 Oct;98(4):763-9. doi: 10.1111/j.1464-410X.2006.06396.x. BJU Int. 2006. PMID: 16796694 Clinical Trial.

6

Secondary hormonal manipulations in prostate cancer.

Ryan CJ. Ryan CJ. Hematol Oncol Clin North Am. 2006 Aug;20(4):925-34. doi: 10.1016/j.hoc.2006.03.005. Hematol Oncol Clin North Am. 2006. PMID: 16861123 Review.

7

Intermittent chemotherapy for metastatic hormone refractory prostate cancer.

Lin AM, Ryan CJ, Small EJ. Lin AM, et al. Among authors: ryan cj. Crit Rev Oncol Hematol. 2007 Mar;61(3):243-54. doi: 10.1016/j.critrevonc.2006.10.002. Epub 2006 Dec 11. Crit Rev Oncol Hematol. 2007. PMID: 17161610 Review.

8

Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).

Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. Ryan CJ, et al. Invest New Drugs. 2007 Oct;25(5):445-51. doi: 10.1007/s10637-007-9050-y. Epub 2007 Apr 26. Invest New Drugs. 2007. PMID: 17458505 Clinical Trial.

9

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.

Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. Lin AM, et al. Among authors: ryan cj. Clin Genitourin Cancer. 2007 Jun;5(5):323-8. doi: 10.3816/CGC.2007.n.011. Clin Genitourin Cancer. 2007. PMID: 17645829 Clinical Trial.

10

Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development.

Hsieh AC, Small EJ, Ryan CJ. Hsieh AC, et al. Among authors: ryan cj. Lancet Oncol. 2007 Oct;8(10):933-9. doi: 10.1016/S1470-2045(07)70316-9. Lancet Oncol. 2007. PMID: 17913662 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

474 results

Search Page

Filters